Technical Analysis for DCPH - Deciphera Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 22.26 -18.25% -4.97
DCPH closed down 18.25 percent on Friday, October 19, 2018, on 5.18 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical DCPH trend table...

Date Alert Name Type % Chg
Oct 19 Volume Surge Other 0.00%
Oct 19 Wide Range Bar Range Expansion 0.00%
Oct 19 Wide Bands Range Expansion 0.00%
Oct 19 Below Lower BB Weakness 0.00%
Oct 19 Down 3 Days in a Row Weakness 0.00%
Oct 19 Lower Bollinger Band Touch Weakness 0.00%
Oct 19 Oversold Stochastic Weakness 0.00%
Oct 18 180 Bearish Setup Bearish Swing Setup -18.25%
Oct 18 Wide Bands Range Expansion -18.25%
Oct 18 Oversold Stochastic Weakness -18.25%

Older signals for DCPH ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Deciphera Pharmaceuticals, LLC is a United-States based clinical-stage biopharmaceutical company. The Company provides treatment for cancer patients. The Company focuses on developing tumor-targeted and immuno-targeted kinase inhibitors. Its switch control inhibitor platform is engaged in producing kinase inhibitors with distinct profiles and anti-cancer effects. Its tumor-targeting therapies include DCC-2618. DCC-2618 is a pan-KIT and PDGFR alpha kinase switch control inhibitor in clinical development for the treatment of KIT and/or Platelet-derived growth factor receptor alpha-driven cancers, including gastrointestinal stromal tumors, glioblastoma multiforme and systemic mastocytosis. Its Immuno-Targeted Therapies include DCC-3014 and Rebastinib. DCC-3014 is a potent and highly-selective immunokinase inhibitor targeting colony stimulating factor receptor 1 (CSF1R). Rebastinib is a TIE2 inhibitor targeting TIE2 expressing macrophages. Rebastinib is in the clinical development stage.
Is DCPH a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 45.61
52 Week Low 15.15
Average Volume 200,003
200-Day Moving Average 30.6684
50-Day Moving Average 34.7772
20-Day Moving Average 32.3305
10-Day Moving Average 28.258
Average True Range 2.4248
ADX 32.99
+DI 8.5939
-DI 39.2545
Chandelier Exit (Long, 3 ATRs ) 33.7256
Chandelier Exit (Short, 3 ATRs ) 29.3244
Upper Bollinger Band 41.9661
Lower Bollinger Band 22.6949
Percent B (%b) -0.02
BandWidth 59.606873
MACD Line -2.8657
MACD Signal Line -2.054
MACD Histogram -0.8116
Fundamentals Value
Market Cap 710.65 Million
Num Shares 31.9 Million
EPS -16.03
Price-to-Earnings (P/E) Ratio -1.39
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 29.93
Resistance 3 (R3) 30.71 28.93 28.65
Resistance 2 (R2) 28.93 26.98 28.54 28.22
Resistance 1 (R1) 25.60 25.78 24.71 24.82 27.80
Pivot Point 23.82 23.82 23.38 23.43 23.82
Support 1 (S1) 20.49 21.87 19.60 19.71 16.72
Support 2 (S2) 18.71 20.67 18.32 16.30
Support 3 (S3) 15.38 18.71 15.87
Support 4 (S4) 14.60